- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
A specialized ultrasound procedure known as transesophageal echocardiography (TEE) offers fine-grained images of the heart's internal architecture from inside the esophagus, which is the tube that connects the mouth and stomach.
A small transducer is attached to the end of a flexible tube during a TEE operation, allowing the transducer to be placed very near the heart by passing through the mouth and into the esophagus. High-frequency sound waves are then sent from the transducer and reflected back to it by the heart's internal structures, producing precise images of the heart.
TEE offers sharper and more precise images of the heart than a conventional echocardiogram, which is carried out through the chest wall because the esophagus is situated close to the heart.
TEE is frequently used to assess congenital cardiac abnormalities, abnormal valve function, and heart function. It can also be used to direct surgical procedures and monitor heart function during surgery.
Although TEE is generally regarded as a safe procedure, there are some risks involved, including minor discomfort during the procedure and uncommon but serious side effects like bleeding, infection, or damage to the esophagus or nearby organs. To reduce pain and guarantee patient safety, TEE is often carried out under sedation or anesthesia.
The Global Transesophageal Echocardiography (TEE) Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Transesophageal echocardiography (TEE) is increasingly becoming a crucial technique in the everyday toolkit of the interventional cardiologist.
TEE, an alternative to the more common transthoracic echo, offers better pictures because the oesophagus is situated right behind the heart.
The development of 3-D/4-D TEE has made the technology the go-to imaging modality for complex new transcatheter structural heart procedures like left atrial appendage (LAA) occlusions, septal defect closures, MitraClip, and transcatheter mitral valve replacements (TMVR).
These procedures have accelerated TEE's acceptance over the past few years, solidifying its place in cath labs and hybrid operating rooms. Transcatheter treatments for heart valve disorders are now available in clinical settings as well as in research settings.
The handheld transesophageal echocardiography (TEE) system was developed by Clarius Mobile Health and ImaCor Inc. as part of a cooperation to manage and direct care for the sickest patients in the intensive care unit (ICU).
With approval from the US Food and Drug Administration, the Zura Handheld Hemodynamic Ultrasound device powered by Clarius offers a quick, clear window to directly see preload and contractility over time, assisting physicians in making the best choices possible.
| Sl no | Topic |
| 1 | Market Segmentation |
| 2 | Scope of the report |
| 3 | Abbreviations |
| 4 | Research Methodology |
| 5 | Executive Summary |
| 6 | Introduction |
| 7 | Insights from Industry stakeholders |
| 8 | Cost breakdown of Product by sub-components and average profit margin |
| 9 | Disruptive innovation in the Industry |
| 10 | Technology trends in the Industry |
| 11 | Consumer trends in the industry |
| 12 | Recent Production Milestones |
| 13 | Component Manufacturing in US, EU and China |
| 14 | COVID-19 impact on overall market |
| 15 | COVID-19 impact on Production of components |
| 16 | COVID-19 impact on Point of sale |
| 17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
| 18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
| 19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
| 20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
| 21 | Product installation rate by OEM, 2023 |
| 22 | Incline/Decline in Average B-2-B selling price in past 5 years |
| 23 | Competition from substitute products |
| 24 | Gross margin and average profitability of suppliers |
| 25 | New product development in past 12 months |
| 26 | M&A in past 12 months |
| 27 | Growth strategy of leading players |
| 28 | Market share of vendors, 2023 |
| 29 | Company Profiles |
| 30 | Unmet needs and opportunity for new suppliers |
| 31 | Conclusion |
| 32 | Appendix |
© 2017-2025 Mobility Foresights Pvt Ltd. All rights reserved.